An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents

Sumio Matzno, Yuka Yamaguchi, Takeshi Akiyoshi, Toshikatsu Nakabayashi, Kenji Matsuyama

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


The possibility of vitamin K3 (VK3) as an anticancer agent was assessed. VK3 dose-dependently diminished the cell viability (measured as esterase activity) with IC50 of 13.7 μM and Hill coefficient of 3.1 in Hep G2 cells. It also decreased the population of S phase and arrested cell cycle in the G2/M phase in a dose-dependent manner. G2/M arrest was regulated by the increment of cyclin A/cdk1 and cyclin A/cdk2 complex, and contrasting cyclin B/cdk1 complex decrease. Finally, combined application demonstrated that VK3 significantly enhanced the cytotoxicity of etoposide, a G2 phase-dependent anticancer agent, whereas it reduced the cytotoxic activity of irinotecan, a S phase-dependent agent. These findings suggest that VK3 induces G 2/M arrest by inhibition of cyclin B/cdk1 complex formation, and is thus useful as an enhancer of G2 phase-dependent drugs in hepatic cancer chemotherapy.

Original languageEnglish
Pages (from-to)1270-1273
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Issue number6
Publication statusPublished - 2008 Jun
Externally publishedYes


  • Etoposide
  • G/M arrest
  • Hepatic cancer
  • Vitamin K

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents'. Together they form a unique fingerprint.

Cite this